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Abstract
Background: While a definitive genetic test for Hereditary Prostate Cancer (HPC) is not yet
available, future HPC risk testing may become available. Past survey data have shown high interest
in HPC testing, but without an in-depth analysis of its underlying rationale to those considering it.
Methods:  Telephone computer-assisted interviews of 400 men were conducted in a large
metropolitan East-coast city, with subsequent development of psychometric scales and their
correlation with intention to receive testing.
Results: Approximately 82% of men interviewed expressed that they "probably" or "definitely"
would get genetic testing for prostate cancer risk if offered now. Factor analysis revealed four
distinct, meaningful factors for intention to receive genetic testing for prostate cancer risk. These
factors reflected attitudes toward testing and were labeled "motivation to get testing,"
"consequences and actions after knowing the test result," "psychological distress," and "beliefs of
favorable outcomes if tested" (α = 0.89, 0.73, 0.73, and 0.60, respectively). These factors accounted
for 70% of the total variability. The domains of motivation (directly), consequences (inversely),
distress (inversely), and positive expectations (directly) all correlated with intention to receive
genetic testing (p < 0.001).
Conclusions: Men have strong attitudes favoring genetic testing for prostate cancer risk. The
factors most associated with testing intention include those noted in past cancer genetics studies,
and also highlights the relevance in considering one's motivation and perception of positive
outcomes in genetic decision-making.
Background
There are several factors to consider in undergoing genetic
testing for cancer risk: potential benefits, possible risks,
psychological distress, and the uncertainty in subsequent
decision-making about prophylactic interventions [1-9].
While the health professional's assessment of the poten-
tial benefits and harms frames the disclosure of informed
consent, the patients' values and expectations are intrinsic
on the decision-making process. Current understanding
of these values and expectations has been primarily
derived from patients considering genetic testing for
breast and colorectal cancers [10]. It remains unclear how
these same factors may influence men's decision making
in testing for hereditary prostate cancer risk [2]. The
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question addressed in this article is what values and expec-
tations influence the intention of men to undergo genetic
testing for prostate cancer risk.
A definitive genetic test for prostate cancer is not clinically
available yet. Current genetic tests are only conducted in
research studies. Several potential genetic loci have been
identified as linked to hereditary prostate cancer, includ-
ing HPC1 [11], MXI1, KAI1, [12] and 1q42.2-q43 on
chromosome 1q. In the future, a test (or set of tests) for
hereditary prostate cancer risk may become available.
Such testing may become an important tool in preventing
prostate cancer, or be useful once prostate cancer is diag-
nosed (e.g., for treatment decisions). Further, it is prudent
for physicians to be prepared for patient requests for
genetic testing, even when there are no strong clinical
indications. Learning why men would accept or refuse
prostate cancer genetic risk information is therefore rele-
vant to the future of testing, and its informed consent.
Informed consent for genetic testing for cancer risk is par-
ticularly controversial in cancers where knowledge of a
positive test result does not provide opportunities for
interventions for favorable outcomes, and a negative
result does not provide reassurance [13]. High stated
intention for genetic testing for prostate cancer risk (over
80%) has been reported in the past [14]. Identification of
a man at genetic risk for prostate cancer presents an
ambiguous dilemma: Should a positive result be followed
by prophylactic surgery, medication, increased surveil-
lance (via PSA testing or rectal examination), or standard
screening recommendations? The knowledge gained
through genetic screening may not necessarily lead to
clear cut recommendations about what the patient should
do next.
This study examines men's beliefs and values toward
interest in prostate cancer genetic testing. A survey instru-
ment was developed for men between 40 and 70 years of
age, exploring their beliefs, attitudes, and concerns in con-
sidering a hypothetical blood test. Exploratory factor anal-
ysis was applied to identify the underlying factor
dimensions. The relative importance of these factors was
then compared to testing intention.
Methods
Study population
The Institutional Review Board (I.R.B.) of the University
of Pennsylvania and US Department of Defense Human
Subjects Review approved the study. Subjects for this
study included healthy outpatient males, identified with
the assistance of the institution's Office of Health Services
Research for demographic characteristics of age, ethnicity,
and absence of past or current history of prostate cancer.
Subjects were sent a letter-invitation to participate with an
opt-out telephone number to call. Inclusion criteria were
that subjects must be English-speaking men in a large met-
ropolitan East-coast city, between the ages of 40 and 70,
with no current evident mental incapacity and no present
or past personal history of prostate cancer. All others were
excluded.
Prostate cancer genetic screening survey questionnaire
Survey development
A 53-item attitude survey instrument was developed. The
items were selected by the collaborators from a pool of
more than 100 preliminary items from the data resulting
from 12 focus groups of 90 lay men regarding their atti-
tude, beliefs, and concerns about prostate cancer genetic
screening [15]. The statements were answered on a 1–5
Likert-type scale ("Strongly Disagree" = 1, "Disagree" = 2,
"Neutral" = 3, "Agree" = 4, and "Strongly Agree" = 5).
Twenty-one items were reverse phrased to counter balance
directionality in the response scale. Items 1, 51, 52, and
53 were intent items: "I would want the genetic test for
prostate cancer risk when it becomes available," "I would
want this test if it could tell me that prostate cancer is
more likely to happen earlier in my life," "I would want
this test if it could tell me that prostate cancer is more
likely to be more life threatening because I have the pros-
tate cancer risk gene," and "I would want this test even if
it does not tell me new information about how early or
aggressive prostate cancer may be in my future,"
respectively.
Telephone interview
The survey was conducted using Computer-Assisted Tele-
phone Interviewing software (MacCATI, Senecio Soft-
ware). The survey instrument was pilot tested in face-to-
face interviews of randomly selected men, age 40–70, in a
primary care office prior to data collection, to verify
understandability of the survey's content and format. For
the telephone survey, a recruitment packet that included
an informed consent letter was first mailed to the prospec-
tive participants. Instructions explained the goals of the
study and gave them an option to opt-out with a toll-free
phone call prior to their interview. An oral informed con-
sent was completed prior to the telephone interview.
Missing data
The number of missing observations ranged from 0 to 13,
with an average of 2.38. Missing data were imputed based
on an imputation model that predicts the missing values
of factors as predicted by all of the other responses,
including the outcome (desire to be tested). The algo-
rithm uses Markov Chain Monte Carlo methods to select
at random a value from the distribution of the possible
values predicted by the missing value model. This method
differs in several respects from other methods of filling in
for missing data, in that with each imputation a differentBMC Medical Genetics 2004, 5:28 http://www.biomedcentral.com/1471-2350/5/28
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value will be imputed for the missing value, thus ensuring
an added dimension of variability in the resulting analy-
ses. The imputation was repeated multiple times. Each
imputation generated an imputed data set. The same fac-
tor analysis was applied and no statistically reliable differ-
ences were found across the imputed data sets. Thus, only
the results from the first imputed data are reported here.
The imputation was carried out by SAS PROC MI.
Factor analysis and reliability statistics
A maximum-likelihood factor analysis with oblique rota-
tion was applied to the 49 non-intent questions to classify
men's non-intent beliefs and attitudes according to their
underlying dimensions. The four questions that directly
probed men's expressed intent were considered a priori as
a separate factor. The factor analysis involved methodo-
logical criteria for data reduction, which included the
rules summarized in Tabachnick [16]. Items with factor
pattern loading lower than .40 were dropped (less than
16% overlapping variance between the item and the asso-
ciated factor). The most salient dimensions were then
retained, accounting for at least 70% of the total variabil-
ity. The internal consistency reliability was assessed by
Cronbach's alpha coefficient [17]. Items that showed the
highest factor pattern loadings for a particular factor were
considered items that measure the attitude associated
with that dimension [18]. Factor scores, with estimated
scores on each of the individual factors had they been
measured directly, were also derived by summing the raw
scores of the items [19].
Results
Demographics
Interviews were completed with 400 respondents with a
cooperation rate of 47% (1675 were contacted, 431
refused to participate either by phone prior to the inter-
view, or at the time of the interview, and 844 were
excluded due to no answer, disconnected telephones, and
death). Table 1 summarizes the respondents' characteris-
tics. Of note, another study by the authors revealed that
no demographic factor had a moderating impact on
intention, except one – in which higher levels of
education correlated with diminished testing intention
[20]. IRB constraints precluded non-respondent data col-
lection for comparison.
Testing intention
About 82% of men interviewed expressed that they "prob-
ably" or "definitely" would take the test if one were
offered now. This high interest increased to 88% if a pos-
itive test result indicates elevated risk in the early onset of
cancer; 93% if it indicates graver prognosis of cancer; and
the stated interest dropped to a still appreciable 68% if no
new information on timing or severity of prostate cancer is
to be learned from the prospective test.
Subscales
Exploratory factor analysis identified four underlying fac-
tors that accounted for 76% of the total variability among
the 49 items probing men's beliefs and attitudes. The four
factors were 1) Motivation, i.e., those values relating how
strongly the respondent wanted the test, and how strongly
the opinions of professionals, spouse, family, relatives,
and friends could have influenced the respondent's own
strength of intent; 2) Consequences, which measured
beliefs with respect to follow-up decision-making and
management; 3) Distress, which assessed fear of losing
health and life insurance, anxiety, and worsening of qual-
ity of life if tested positive; and 4) Positive Expectations,
which described beliefs in how the test results will confer
useful information in family risk and favorable outcomes.
The four intent items were added separately as the fifth
subscale 5) Intention  directly probing the respondent's
stated intent. Table 2 summarizes the subscales, their
respective internal consistency, and the factor loadings of
their constituent items.
Table 1: Respondent characteristics













< High school 86 22
High school graduate/some college 149 37
College graduate 141 35
Post-graduate degree 23 6
No response 1 0
Annual household income
$15,000 or less 17 4
$15,001 – $45,000 74 19
$45,000 – 75,000 84 22
$75,000 – $105,000 90 23
More than $105,000 107 28
No response 28 7
Marital status
Married 319 80
Steady relationship but not married 23 6
Separated or divorced 26 7
Single 25 6
Widowed 7 2BMC Medical Genetics 2004, 5:28 http://www.biomedcentral.com/1471-2350/5/28
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Table 2: Subscales, internal consistency, and factor item loadings
Factors / statements (internal consistency statistics) Factor pattern loading
Motivation
Subscale 1: Motivation (alpha = 0.89, 37% variability)
Even if other relatives did not want me to, I would get genetic testing. 0.80
Even if my children did not want me to, I would get genetic testing. 0.77
I would get genetic testing if my friends wanted me to. 0.73
Even if my friends did not want me to, I would get genetic testing. 0.72
I would get testing if other relatives wanted me to. 0.68
Even if my wife or partner did not want me to, I would get genetic testing. 0.68
Even if a genetic testing specialist recommended against it, I would get 
genetic testing.
0.60
I would get testing if my children wanted me to. 0.59
Even if my doctor recommended against it, I would get genetic testing. 0.57
I would get testing if a genetic testing specialist recommended it. 0.46
I would get testing if my wife or partner wanted me to. 0.43
Consequences
Subscale 2: Consequences and actions after knowing the test result (alpha = 
0.73, 23% variability)
I find that my concerns about getting prostate cancer interfere with my 
every day life. [R]
0.56
I don't want testing unless there is a prostate cancer cure. [R] 0.54
If I know I have the prostate cancer risk gene, it will make me feel guilty. 
[R]
0.53
I'll have to make a quick treatment decision if I know I have the prostate 
cancer risk gene. [R]
0.52
If I know I have the prostate cancer risk gene, I will make me want to end 
my life. [R]
0.51
If I don't have the prostate cancer risk gene, I will be able to put my mind 
at rest about prostate cancer. [R]
0.51
I don't want testing unless it can tell me whether I have prostate cancer 
now. [R]
0.49
I would not want to have children if I know I have the prostate cancer risk 
gene. [R]
0.44
I would want to put off testing as long as I can. 0.42
Distress
Subscale 3: Psychological distress (alpha = 0.73, 10% variability)
I am concerned I will lose or not be able to get LIFE insurance if I get the 
genetic testing for prostate cancer risk. [R]
0.64
If I know I have the prostate cancer risk gene, it will make me anxious. [R] 0.59
I am concerned I will lose or not be able to get HEALTH insurance if I get 
the genetic testing for prostate cancer risk. [R]
0.57
If I know I have the prostate cancer risk gene, I will feel worse about 
myself. [R]
0.46
My life will get worse if I know I have the prostate cancer risk gene. [R] 0.46




Subscale 4: Beliefs in favorable outcomes if tested (alpha = 0.60, 7% variability)
I believe this test could save my life. 0.52
The more I know about my risk for prostate cancer, the better I will feel 
about testing.
0.51
The test results might provide valuable information on prostate cancer risk 
to my family members.
0.45
If I know I have the prostate cancer risk gene, my doctor may want to do 
more tests.
0.42BMC Medical Genetics 2004, 5:28 http://www.biomedcentral.com/1471-2350/5/28
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Overall, the five subscales showed satisfactory internal
consistency. The four items within Intention scale,
although grouped together a priori for their content,
showed a good internal consistency alpha coefficient at
0.79. Among the 49 items that probed men's beliefs,
values, and attitudes, the 11 items that loaded high on
Motivation accounted for most of the variability (37%)
with a very high alpha coefficient (0.89). The nine items
in Consequences accounted for the next largest amount of
variability (23%) with an alpha coefficient of 0.73. The six
items in Distress accounted for 10% of the variability with
an alpha of 0.73. Finally, the four items in Positive Expec-
tations accounted for 7% of the variability with an alpha
of 0.60.
The factor pattern loadings reflect the correlation between
an individual item and its subscale. For example, Table 2
shows that Motivation is strongly associated with the item
"even if other relatives did not want me to, I would get
genetic testing." (Loading value = 0.80). Respondents
with high motivation tended not to be influenced by
other relatives. Importantly, the less one is influenced by
a relative's opinion, the more likely he is to be motivated
to get testing. Conversely, a man who was easily influ-
enced by his spouse or children was somewhat less likely
to be motivated toward testing. This latter set of values
may reflect the desire for more information and counsel.
The inter-correlations between the subscales are summa-
rized in Table 3, and reveal how these subscales were asso-
ciated with one another and how they affected intent. The
respondents' motivation (regarding the influence of oth-
ers in their decision) was positively correlated with inten-
tion to test (r = 0.69, p < 0.001). There was also a positive
and statistically significant correlation between one's
motivation and one's expectations that genetic screening
may lead to favorable outcomes for the gene carrier and
his family (r = 0.39, p < 0.001). Concerns about the con-
sequences of a positive result, including the uncertainties
of test validity and accuracy, and the availability of subse-
quent interventions, were positively correlated with dis-
tress (r = 0.34, p < 0.001) and diminished intention to test
(r = -0.16, p < 0.01). Distress-based values were associated
with diminished intention to test (r = -0.17, p < 0.001).
Intent
Subscale 5: Intention (alpha = 0.79)
I would want the genetic test for prostate cancer risk when it becomes 
available.
-
I would want the test if it could tell me that prostate cancer is more likely 
to happen earlier in my life.
-
I would want this test if it could tell me that prostate cancer is more likely 
to be more life threatening because I have the prostate cancer risk gene.
-
I would want this test even if it does not tell me now information about 
how early or aggressive prostate cancer may be in my future.
-
[R] – Item reversed in coding for analysis
N.B. – Intent items were not included in the factor analysis, thus there are no available data on pattern loadings and variance.
The following factors did not load onto the four value-based factor domains, and 
were omitted from further analysis:
I want to wait on testing until it is shown to be very accurate.
I will not be able to keep my job, or get a promotion, if I know I have the 
prostate cancer risk gene.
If I know I have the prostate cancer risk gene, my doctor might pressure 
me to receive treatment.
Nothing can be done to prevent prostate cancer.
Changes in my lifestyle can reduce my risk of cancer.
I only want my family doctor to do this test for prostate cancer risk.
I don't want testing unless I can do something to prevent prostate cancer.
The government could use my test results in ways I do not want.
I often worry about getting prostate cancer
If I know I do not have the prostate cancer risk gene, I won't need rectal 
exams or PSA tests as often.
No matter my results, I would want testing if it helps find a cure.
I don't want the test if my health care coverage does not pay for it.
I would want to get tested because I just want to know if I have the gene 
for prostate
No one should give out my test results to anyone else without my 
permission.
I would get testing if my doctor recommended it.
Table 2: Subscales, internal consistency, and factor item loadings (Continued)BMC Medical Genetics 2004, 5:28 http://www.biomedcentral.com/1471-2350/5/28
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Finally, respondents who expected favorable outcomes
were associated with increased intention to test (r = 0.48,
p < 0.001).
Discussion
These data demonstrate that men in the general public,
aged 40 to 70 years without a personal history of prostate
cancer, consider prostate cancer genetic testing related to
four value-based factor domains, similar to past literature
findings on genetic testing for hereditary cancer risk. The
motivation factor, which measures values of influence by
others, is the strongest decision factor in guiding their opt-
ing for the test. More than 80% of men interviewed would
consider getting tested if the test was available now. Their
stated intention, as measured by the four intent items, is
highly correlated with how strongly they feel they are
motivated toward the test and inversely related to family
influences. Men with strong motivation to get tested also
have significantly lower concerns about psychological dis-
tress and higher levels of positive expectations. The rec-
ommendations of physicians and geneticists are
important to men's expressed motivation, although the
professionals did not appear to be more influential than
their kin.
A respondent is more likely to want the test if he believes
that the test may be informative of family risk and may
lead to early identification and prevention of cancer (as
part of the Positive Expectations domain). The influences
of kin, along with beliefs in family risk, highlight the
importance of reviewing family-related risk information
as part of genetic consultation and informed consent.
Men undergoing informed consent for hereditary prostate
cancer risk in the future not only should be provided
information on what genetic testing can and cannot do for
them, but also what the test results could mean for others
surrounding them (as evidenced by the influences of fam-
ily, etc.).
Prior hereditary breast cancer (BRCA) and colorectal can-
cer (CRC) literature has noted anecdotally that perception
of benefit to one's family influences genetic test uptake.
Eliciting patient perceptions of concerns regarding their
family may be beneficial to consider in oncology genetic
testing generally. Similar to this literature, intention was
found to be influenced by the respondent's concerns
about test validity, test accuracy, and by the availability of
interventions that may lead to favorable outcomes. Not
surprisingly, men who were concerned about potential
psychological distress were less likely to want the test. One
unanswered question is how men's anticipatory distress
and expected adverse consequences may affect how family
risk information is interpreted and discussed. Few men in
our study anticipated high levels of distress. Although lit-
erature data clearly show elevated distress among patients
and their family members [21]. More research is needed
to better establish the family-risk construct and how it
may be influenced by other beliefs and values.
The present study has limitations. Given the exploratory
nature of factor analysis, these data are aimed at identify-
ing coherent subsets of variables for data reduction, not at
identifying specific attitude statements that discriminate
skeptics from supporters. Nevertheless, the reduced set of
34 items is the most important among the administered
57 items, and comprises a coherent and reliable assess-
ment tool of eliciting values and intention toward testing.
This item set can thereby serve as a foundation for a con-
firmatory health beliefs model, using Structural Equation
Modeling techniques to better elucidate the interactions
of these value-based domains [22]. Also, we noted that
this population had somewhat higher income and educa-
tion levels than the overall Philadelphia Consolidated
Metropolitan Statistical Area (CMSA). 51% of men had
over $75,000 income, compared with the 32% in the Phil-
adelphia CMSA 2000 census year dataset, and 41% had
completed a Bachelor's degree or higher, compared with
28% in the CMSA. These differences may be due to afflu-
ent subjects living in suburban counties in the metropoli-
tan Philadelphia area, who then self-select to be seen by
physicians in the University of Pennsylvania system. As
noted above, our prior work demonstrated no demo-
graphic differences except education (with more educa-
tion correlating with diminished intention). Thus, we do
Table 3: Inter-correlations between subscales
Motivation Consequences Distress Positive Expectations
Motivation -
Consequences -0.08 -
Distress -0.19* 0.34* -
Positive Expectations 0.39* -0.02 -0.003 -
Intention 0.69* -0.16* -0.17* 0.48*
* p < 0.001BMC Medical Genetics 2004, 5:28 http://www.biomedcentral.com/1471-2350/5/28
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not foresee an adverse impact of these discrepancies on
the overall outcomes of our analysis [20].
Future directions of this research may include exploring
the relationship between stated intent in prostate cancer
genetic screening and actual testing behavior when testing
is available. Studies have shown that expressed intention
does not necessarily translate to actual behavior in taking
genetic tests for breast and colorectal cancers [10,23-29].
The same discrepancy between attitude and behavior may
exist when a test for prostate cancer is available for the
general public. Our data suggest that potential psycholog-
ical distress, worries about test validity, insurance, confi-
dentiality, and the uncertainties in subsequent
intervention decisions may need to be balanced with fam-
ily considerations when testing becomes available [30].
Conclusions
Men in this survey voiced strong attitudes favoring future
genetic testing for prostate cancer risk. In the past decade
and a half, genetic testing for a variety of cancers concen-
trated on several key concepts: i.e., stigmatization, pri-
vacy, anxiety/stress, and the need to know. These notions
of stigma and psychological impact were not as relevant in
this population regarding prostate cancer risk genetic test-
ing. For examples, the following statements did not show
strong enough factor loadings to warrant their inclusion,
such as "I will not be able to keep my job, or get a promo-
tion, if I know I have the prostate cancer risk gene," "The
government could use my test results in ways I do not
want," "I often worry about getting prostate cancer," and
"I would want to get tested because I just want to know if
I have the gene for prostate cancer."
The most relevant aspect of data reported herein is that
they begin to shed new light on the relevance of "others."
How men were concerned about the impact on and the
effects upon one's family were reflected in the factor anal-
ysis. As a result, future informed consent may likely
include considerations of 1) how the test results will affect
their own future lives, and 2) how the test results will
affect their family members. The latter consideration is
seldom brought into the informed consent process in the
genetic counseling but may be relevant to the patient.
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